Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for type 2 diabetes management (Mounjaro) and chronic weight management (Zepbound) in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity, as an adjunct to diet and physical activity
Drugs on higher tiers have higher copays than drugs on lower tiers
We provide private patient rooms and have separate specialized units for newborn, pediatric, medical and surgical intensive care
Your body is not betraying you it is responding to years of adaptation, stress, and metabolic defense
By modulating the structure and function of tumor blood vessels through normalization, disruption, or remodeling, NP-based strategies can substantially improve drug penetration, immune cell infiltration, and overall therapeutic outcomes